These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 37555275)

  • 1. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.
    Pérez-Vargas J; Worrall LJ; Olmstead AD; Ton AT; Lee J; Villanueva I; Thompson CAH; Dudek S; Ennis S; Smith JR; Shapira T; De Guzman J; Gang S; Ban F; Vuckovic M; Bielecki M; Kovacic S; Kenward C; Hong CY; Gordon DG; Levett PN; Krajden M; Leduc R; Boudreault PL; Niikura M; Paetzel M; Young RN; Cherkasov A; Strynadka NCJ; Jean F
    Emerg Microbes Infect; 2023 Dec; 12(2):2246594. PubMed ID: 37555275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics.
    Pérez-Vargas J; Shapira T; Olmstead AD; Villanueva I; Thompson CAH; Ennis S; Gao G; De Guzman J; Williams DE; Wang M; Chin A; Bautista-Sánchez D; Agafitei O; Levett P; Xie X; Nuzzo G; Freire VF; Quintana-Bulla JI; Bernardi DI; Gubiani JR; Suthiphasilp V; Raksat A; Meesakul P; Polbuppha I; Cheenpracha S; Jaidee W; Kanokmedhakul K; Yenjai C; Chaiyosang B; Teles HL; Manzo E; Fontana A; Leduc R; Boudreault PL; Berlinck RGS; Laphookhieo S; Kanokmedhakul S; Tietjen I; Cherkasov A; Krajden M; Nabi IR; Niikura M; Shi PY; Andersen RJ; Jean F
    Antiviral Res; 2023 Jan; 209():105484. PubMed ID: 36503013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals.
    Pérez-Vargas J; Lemieux G; Thompson CAH; Désilets A; Ennis S; Gao G; Gordon DG; Schulz AL; Niikura M; Nabi IR; Krajden M; Boudreault PL; Leduc R; Jean F
    Antiviral Res; 2024 May; 225():105869. PubMed ID: 38548023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.
    Li P; Kim Y; Dampalla CS; Nhat Nguyen H; Meyerholz DK; Johnson DK; Lovell S; Groutas WC; Perlman S; Chang K-O
    mBio; 2024 Feb; 15(2):e0287823. PubMed ID: 38126789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants.
    Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY
    Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Takashita E; Fujisaki S; Morita H; Nagata S; Miura H; Nagashima M; Watanabe S; Takeda M; Kawaoka Y; Hasegawa H
    Antiviral Res; 2023 Aug; 216():105671. PubMed ID: 37451629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Omicron Variant in Medicinal Chemistry Research.
    Souza Rocha W; Zhan P; Ferreira da Silva-Júnior E
    Curr Top Med Chem; 2023; 23(17):1625-1639. PubMed ID: 37055893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Epidemiology of SARS-CoV-2 Omicron Sub-Lineages Isolated from Turkish Patients Infected with COVID-19.
    Sayan M; Arikan A; Sanlidag E
    Viruses; 2023 Apr; 15(5):. PubMed ID: 37243152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of peptide-functionalized or unfunctionalized selenium nanoparticles for the passivation of SARS-CoV-2 variants and the respiratory syncytial virus (RSV).
    Nahhas AF; Webster TJ
    Colloids Surf B Biointerfaces; 2024 Jan; 233():113638. PubMed ID: 37995630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berbamine suppresses intestinal SARS-CoV-2 infection via a BNIP3-dependent autophagy blockade.
    Cloherty APM; Rader AG; Patel KS; Pérez-Vargas J; Thompson CAH; Ennis S; Niikura M; Wildenberg ME; Muncan V; Schreurs RRCE; Jean F; Ribeiro CMS
    Emerg Microbes Infect; 2023 Dec; 12(1):2195020. PubMed ID: 36951188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
    Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
    Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling.
    Alvarez N; Adam GC; Howe JA; Sharma V; Zimmerman MD; Dolgov E; Rasheed R; Nizar F; Sahay K; Nelson AM; Park S; Zhou X; Burlein C; Fay JF; Iwamoto DV; Bahnck-Teets CM; Getty KL; Lin Goh S; Salhab I; Smith K; Boyce CW; Cabalu TD; Murgolo N; Fox NG; Mayhood TW; Shurtleff VW; Layton ME; Parish CA; McCauley JA; Olsen DB; Perlin DS
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.